Ahead of ARVO 2025 next week where Emmes is poised to launch the first dedicated ophthalmology clinical trial technology platform, we spoke with Saqib Parkar, ...

“All organisations, even the most renowned and successful, sometimes make the right things too hard and the wrong things too easy.”1 Sutton and Rao address this prob...

Europe’s regulatory environment is shifting fast. In the clinical trials space, recent years have brought sweeping changes, shaped by initiatives like the General Da...

Rare diseases, also known as orphan diseases, affect an estimated 300 million people worldwide, yet each individual condition impacts a relatively small patient popu...

Committees (DMCs) has never been more critical in ensuring patient safety and trial integrity, especially as clinical trials become more complex and globalised. In r...

The discovery and integration of cancer biomarkers into oncology research has transformed how cancer is detected, diagnosed and treated. As precision medicine contin...

The need for a UK national screening programme to enable early detection of prostate cancer is now more important than ever, with one in six men receiving a prostate...

 Data in life sciences is more than a mere byproduct of research; it is a driving force behind innovation. By harnessing extensive datasets, organisations can s...

By 2026, IDMP compliance will become more challenging for all pharmaceutical companies operating in the EU, due to the broader adoption of the IDMP data model. Now, ...

Deep learning technology can be very strong at identifying complex patterns within large data sets and mapping them to simple classifications like diagnosing a certa...